GILD is growing HIV business, but not nearly at the rate that its HCV business is declining Cash = 36.7Bn on 12/31/17 Debt is ~33Bn repatriating 5.5Bn in 2018 to reduce debt will pay 0.57/share divy in 2018 spent 12.57Bn to acquire Kite and Cell Design Labs in 2017 Avoid, too many parts moving in different directions.